Pharmarise Holdings Corp.

As of May 31, 2026, Pharmarise Holdings Corp. carries a market capitalization of 5.82B, placing it among publicly traded companies globally. Its enterprise value stands at 14.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pharmarise Holdings Corp.'s next confirmed earnings release is scheduled for December 17, 2026.

As of May 31, 2026, Pharmarise Holdings Corp. has 11.50M shares outstanding.

These figures are as of May 31, 2026.

As of May 31, 2026, Pharmarise Holdings Corp. maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended May 31, 2026.

As of the close on October 22, 2026, Pharmarise Holdings Corp.'s stock has declined approximately 4.15% over the past 52 weeks. The 50-day moving average sits at 503.52, while the 200-day moving average is 509.27.

As of May 31, 2026, Pharmarise Holdings Corp. holds 6.02B in cash and equivalents against 15.15B in total debt, resulting in a net debt position of 8.58B. Total book value stands at 6.84B, with working capital of -846.00M providing operational flexibility.

Pharmarise Holdings Corp.'s most recent stock split took place on November 27, 2013 with a 1:100 split ratio.